So what was the clinical question you were trying to answer?

So we wanted to know what the benefits and harms are of lower systolic blood pressure targets.

So we kind of looked at all the evidence and did a search to see what was out there.

And we landed on several meta-analyses.

Okay.

But we focused on one particular one that was a meta-analysis of six of the largest randomized controlled trials.

So it included like SPRINT from 2015.

And there were some issues, Sam, about how the blood pressure was measured, right? Yeah.

Okay.

Um, but we focused on one particular one that was a meta-analysis of six of the largest randomized controlled trials.

So it included, like, SPRINT from 2015.

It included, like, the most recent ones, BP-ROAD and ESPRIT from 2024.

So in total, there was over 80,000 participants.

Um, and this was a meta-analysis that was done using participant-level data, so that's also a bit of an advantage.

Um, and the average age was 64, and about 45% of them had a 10-year cardiovascular risk that was over-- that was 20% or more.

And it act-- This also comes back to a little bit of the context that we're gonna talk about, right? Because the main clinical trial that looked at this was the SPRINT trial, and there were some issues, Sam, about the, how the blood pressure was measured, right?